Skip to main content
PLOS One logoLink to PLOS One
. 2022 Oct 13;17(10):e0275793. doi: 10.1371/journal.pone.0275793

The analgesic efficacy of pericapsular nerve group block in patients with intertrochanteric femur fracture: A randomized controlled trial

Mingjian Kong 1,*, Yan Tang 2,#, Fei Tong 1,, Hui Guo 1,, Xin Lei Zhang 1,#, Lei Zhou 3, Hua Ni 4, Bin Wang 3, Yunqing Liu 1, Jindong Liu 2
Editor: Rizaldy Taslim Pinzon5
PMCID: PMC9562218  PMID: 36227845

Abstract

Background

The aim of this study is to evaluate analgesic efficacy of pericapsular nerve group (PENG) block in patients with intertrochanteric femur fracture (IFF).

Methods

This double-blinded randomized controlled trial in patients with IFF scheduled for proximal femoral nail antirotation (PFNA) between December 2020 and November 2021. The primary outcome was VAS scores during exercising at 6 h after surgery; secondary outcomes were pain during exercising and rest, intraoperative dose of remifentanil, cumulative dose of postoperative fentanyl, postoperative analgesia satisfaction scores, and ratio of quadriceps weakness.

Results

A total of 50 patients were randomly divided into PENG block group (n = 25) or fascia iliaca compartment block (FICB) group (n = 25). Exercising VAS scores at 6 h after surgery were significantly lower in PENG block group than that in FICB group (2 (2, 4) vs. 6 (4, 7), P < 0.001). The intraoperative dose of remifentanil and cumulative dose of postoperative fentanyl by patient-controlled intravenous analgesia within 24 h after surgery in PENG block group were significantly lower than in FICB group (both P < 0.001). Postoperative analgesia satisfaction scores in PENG block group were significantly higher than those in FICB group (P = 0.016). The ratio of quadriceps weakness at 6 h after surgery was significantly higher in FICB group than PENG block group (48% vs. 0%, P < 0.001).

Conclusions

Compared to FICB, ultrasound-guided PENG block may provide better postoperative pain relief in patients with IFF, with less pronounced quadriceps weakness.

Introduction

Intertrochanteric femur fracture (IFF) is a common traumatic event in elderly patients, where it accounts for approximately 45% to 50% of all hip fractures [1]. IFF often causes severe pain, up to 9 points in the movement-associated median pain score [2], limiting the activities of patients even after surgery, and increasing the incidence of deep venous thrombosis of the lower extremities, pulmonary infection and mortality [3]. Therefore, effective analgesia could improve postoperative quality of life, promote early postoperative functional exercises and reduce complications.

Peripheral nerve blocks (PNB) were shown to have less influence on the hemodynamics, respiration function and consciousness, compared to systemic pain relief options. Notably, PNBs are recommended as the first-line analgesia program for hip surgeries, with the ability to reduce doses of opioids, shorten the postoperative recovery time, and decrease the risk of pneumonia [4]. Among the most common PNB locations, fascial iliaca compartment is a space between the iliopsoas muscle and the iliac fascia, where three principal lumbar plexus nerves of the thigh are located, namely the femoral, lateral cutaneous, and obturator nerve. Fascia iliaca compartment block (FICB) is safe and simple, commonly used for perioperative analgesia of hip fracture, which in theory can simultaneously block femoral nerve, lateral femoral cutaneous nerve and obturator nerve, to obtain distal lumbar plexus block effect. Compared with intravenous analgesia, FICB can alleviate postoperative pain and decrease morphine consumption after hip surgery [5, 6]. However, it has been reported that in some cases FICB does not provide the adequate analgesia or decrease in the opioid consumption after total hip arthroplasty [7], due to the failure of FICB to block obturator nerve [8].

Pericapsular nerve group (PENG) block, which targets the articular branches of femoral nerve, obturator nerve and accessory obturator nerve, was firstly introduced by Girón-Arango in 2018 [9]. PENG block have a potential for hip fracture, with the ability to reduce the median of dynamic pain score by 7 points in hip fracture patients which is superior to other PNBs [9]. Recently, several case reports have shown that PENG block provides a sufficient analgesia during hip fracture surgeries without a potential influence on the quadriceps muscle strength [10, 11], but prospective studies on the analgesic efficacy of PENG block in comparison to other, more traditional PNB approaches are still needed.

Therefore, the primary objective of this study was to compare the analgesic effects of ultrasound-guided PENG block and FICB in IFF patients undergoing proximal femoral antirotation (PFNA) under general anesthesia. A secondary objective was to compare the effects of PENG block and FICB on postoperative muscle strength in patients. At the same time, the related complications of PENG block were observed, and the safety of its clinical application was discussed.

Methods

Study design and subjects

This manuscript adheres to the applicable CONSORT guidelines. This RCT included patients with IFF diagnosed by radiography criteria proposed by Marsh [12], and receiving PFNA under general anesthesia at the department of Orthopaedics in the Second Affiliated Hospital of Xuzhou Medical University between December 2020 and November 2021. The study was approved by the Ethics Committee of The Second Affiliated Hospital of Xuzhou Medical University ([2020] 102901) and written informed consent was obtained from all subjects participating in the trial. Before patient enrolled, the study was registered at chictr.org.cn (identifier: ChiCTR2000039749, principal investigator: Fei Tong, Date of registration: November 7, 2020). The ethics committee supervises the whole process of the experiment and ensures the safety of patients.

Inclusion criteria: 1) 65–85 years of age; 2) American Society of Anesthesiologists (ASA) grade I-III; 3) preoperative resting visual analogue scale (VAS) scores ≥ 4 points [13].

Exclusion criteria: 1) Unable to orally communicate; 2) Body mass index (BMI) > 30 kg/m2 or <18.5kg/m2; 3) Allergic to the study drugs; 4) Liver or renal insufficiency; 5) Opioid addiction or dependence; 6) Cognitive impairment; 7) Neuromuscular disorders; 8) Local infection of nerve block; 9) Surgery time > 2 hours (Fig 1).

Fig 1. Flow chart of the present study.

Fig 1

Randomization and blinding

Patients were randomly assigned to the PENG group and the FICB group at 50% of each group according to a computer-generated random number table. This study was blinded for the anesthesiologists, data collectors, statistical analysts, and patients. A staff member A, who was not involved in the following research, delivered the card with the grouping in the opaque envelope with the random number on the cover. After the patient enters the operating room, A handed over the envelope to operator B. Upon opening the envelope, B clarified the method of nerve block and performed corresponding operations. B was only responsible for the nerve block operation, and has no knowledge regarding the content of the following research. Before and after the completion of the B operation, the special data collector C will collect the pain score and other data. C was blind to the classification of the nerve block, the subsequent anesthesia work was performed by an uninformed anesthesiologist. All data of postoperative patients were collected by C, and the entire procedure was blinded to patients.

Intervention

Patients in both groups were fasting for 8 h, with drinking prohibited 2 h prior to the surgery. Electrocardiography, pulse oxygen saturation, invasive radial arterial pressure, and bispectral index (BIS) were continuously monitored during the surgery.

Patients in PENG group received PENG block as described by Girón-Arango [9]. They were placed in the supine position, and a low-frequency curvilinear ultrasound probe (2–6 MHz, Sonosite) was horizontally placed above the anterior superior iliac spine and moved toward the pubic bone. After the anterior inferior iliac spine was visualized, the probe was rotated parallel to the pubic branch until the anterior inferior iliac spine, iliopsoas eminence, femoral artery, iliopsoas muscle and its tendons were clearly visualized. A 22G puncture needle was punctured outside-in under the guidance of ultrasound. 2 mL of normal saline was injected until the tip of the puncture needle reach the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly to identify the correct location of the tip, followed by injection of 30 mL of 0.375% ropivacaine (Naropin, AstraZeneca, Fig 2).

Fig 2. Representative image and ultrasound scans of the patient receiving PENG block.

Fig 2

(A) Patients’ position and the placement of the probe. (B) Ultrasound-guided tracing of the puncture needle (white arrow). (C) Deposition of local anesthetics. * Iliopsoas tendon is marked on Fig 1B and 1C. PENG, pericapsular nerve group; AIIS, anterior inferior iliac spine; IPE, iliopubic eminence; FA, femoral artery; LA, local anesthetics.

Patients in FICB group received FICB as described by Dolan [14]. They were placed in the supine position, and a high-frequency line probe (6-13MHz, Sonosite) was placed near the inguinal ligament, which clearly visualized the femoral artery, femoral vein, iliac muscle and sartorius muscle. At 1 cm under the line connecting the pubic tubercle and anterior superior iliac spine, a 22G puncture needle was punctured outside-in. 2 mL of normal saline was injected until the tip of the puncture needle reach the musculofascial plane between the iliac fascia and iliopsoas muscle to identify the correct location of the tip, followed by injection of 30 mL of 0.375% ropivacaine (Fig 3).

Fig 3. Representative image and ultrasound scans of the patient receiving FICB.

Fig 3

(A) Patients’ position and the placement of the probe. (B) Tracing of the puncture needle (white arrow). (C) Deposition of local anesthetics. FICB, fascia iliac compartment block; FA, femoral artery; FN, femoral nerve; FI, Iliac fascia; IM, iliacus muscle; LA, local anesthetics.

Patients in both groups were intravenously administrated with 1 μg/kg fentanyl, 1.5–2 mg/kg propofol and 0.1 mg/kg atracurium for induction of anesthesia. General anesthesia was maintained by administration of 1.0–1.5% sevoflurane and 0–0.3 μg/kg/min remifentanil (according to the BIS and hemodynamics). All patients were administrated with 15 ml of 0.375% ropivacaine for local infiltration anesthesia before suturing. After removing the laryngeal mask in the operating room, they were sent to the post-anesthesia care unit (PACU).

In the surgical ward, as addition to patient-controlled intravenous analgesia (PCIA) pump with a 10-μg fentanyl bolus and a 20-min lockout period with no background, all patients received regular intravenous Flurbiprofen axetil 50 mg every 24 hours during 48 hours.

Outcomes

The primary outcome was the postoperative pain during exercising (passive elevation of the lower limb at 15°) at 6 h (T2) after surgery. Postoperative pain was evaluated by a VAS ranging from 0 to 10, in which 0 indicates no pain and 10 indicates extreme pain; a pain score of 1–3 was considered to indicate mild pain [15].

The secondary outcomes included VAS scores at rest and during exercise at different time points, dosage of remifentanil and fentanyl, rate of quadriceps motor block, postoperative analgesia satisfaction scores and block-related complications and postoperative adverse effects.

The VAS scores at rest and during exercise at different time points referred to scores before nerve block (T0), 30 min after nerve block (T1), 24 h (T3), 48 h (T4) and 72 h (T5) postoperatively and the rest VAS scores at 6 h postoperatively.

Intraoperative dose of remifentanil, postoperative cumulative dose of fentanyl at 24 h and 24~48 h were recorded, as well as block-related complications and postoperative adverse effects, such as postoperative nausea, vomiting, dizziness, delirium, urinary retention and deep venous thrombosis of lower extremities. Postoperative analgesia satisfaction scores were graded as 0 point, dissatisfied; 1 point, average; 2 points, fair; 3 points, satisfied; and 4 points, very satisfied.

Quadriceps motor block was assessed using knee extension at 6 h after surgery. Knee extension was evaluated in a supine position with the patient’s hip and knee flexed at 45° and 90°, respectively. Knee extension was graded according to a 3-point scale: 0 = no block, 1 = paresis (decreased ability to extend the leg), 2 = paralysis (inability to extend the leg) [16].

Statistical analysis

The preliminary pilot study involving 10 elderly patients with intertrochanteric femur fracture showed that the VAS scores at 6 h after surgery were 3.4 ± 1.9 (mean ± SD, PENG block group) and 5.4 ± 2.1 (mean ± SD, FICB group) respectively. Based on the pilot study, and considering a 20% of dropout rate (α = 0.05, power of test = 90%), we determined that a sample size of 25 patients per group.

Normal distribution of continuous data was assessed using the Shapiro-Wilk test, the Levene test was used to verify homogeneity. Continuous data with normal distribution were expressed as mean ± standard deviation (SD) and compared using the Student’s t-test; Otherwise, data were expressed as the median and quartiles, and compared using the Mann-Whitney U-test. Categorical data were expressed as numbers and percentages, and compared using the Chi-square test or Fischer’s exact test. Statistical analyses were performed using IBM SPSS Statistics 25 (IBM, Armonk, NY, USA). Two-tailed P value < 0.05 was considered statistically significant.

Results

62 elderly patients were screened for eligibility for the study by the research assistant (Fig 1), 12 patients were excluded or declined participation. Finally, 50 patients were randomly divided into PENG block group (n = 25) and FICB group (n = 25), with the mean age of 73.4 ± 5.9 and 72.8 ± 4.8 years respectively (Table 1).

Table 1. Characteristics of patients.

Characteristics PENG block group (n = 25) FICB group (n = 25) P
Age (year, mean ± SD) 73.4 ± 5.9 72.8 ± 4.8 0.627
Male/female [n (%)] 0.569
 Male 12 (48) 10 (40)
 Female 13 (52) 15 (60)
Height (m, mean ± SD) 1.66 ± 0.07 1.64 ± 0.06 0.417
Body weight (Kg, mean ± SD) 70.9 ± 9.0 69.8±8.4 0.663
BMI (Kg/m2, mean ± SD) 25.6 ± 1.9 25.7 ± 1.9 0.906
ASA grade II/III [n (%)] 0.508
 Grade II 7 (28) 5 (20)
 Grade III 18 (72) 20 (80)
VAS scores at rest [M (IQR)] 5 (5, 6) 6 (5, 6.5) 0.622
VAS scores on exercise [M (IQR)] 9 (7, 10) 8 (7, 9) 0.417
Surgery time (min, mean ± SD) 87.7 ± 20.7 87.6 ± 18.7 0.989
T1-T2 time (min, mean ± SD) 477.72±19.67 477.64±17.89 0.988

PENG, pericapsular nerve group block; FICB, fascia iliac compartment block; BMI, body mass index; ASA, American Society of Anesthesiologists; VAS, visual analogue scale; M, median value; IQR, interquartile range.

As demonstrated in Table 2, exercising VAS scores in PENG block group at 6 hour after surgery were significantly lower than those of FICB group (2(2,4) VS.6(4,7)), (P < 0.001). The resting VAS scores in PENG block group at T1-T3 were significantly lower than those of FICB group (all P < 0.001) as well as exercising VAS scores at T1-T4 (all P < 0.001, Table 2).

Table 2. VAS scores in patients receiving PENG or FICB at different time points.

Characteristics Time points PENG block Group (n = 25) FICB Group (n = 25) P
VAS scores at rest [M (IQR)] T0 (before nerve block) 5 (5, 6) 6 (5,6.5) 0.622
T1 (30 min after block) 2 (1,2.5) 3 (2,4) 0.001
T2 (6 h postoperatively) 2 (1,2) 3 (2,4) <0.001
T3 (24 h postoperatively) 2 (1,3) 3 (3,4) 0.001
T4 (48 h postoperatively) 3 (2,4) 4 (3,4) 0.051
T5 (72 h postoperatively) 3 (2,4) 3 (2,4) 0.442
VAS scores on exercise [M (IQR)] T0 (before nerve block) 9 (7,10) 8 (7,9) 0.417
T1 (30 min after block) 3 (2,3) 5 (3,6.5) <0.001
T2 (6 h postoperatively) 2 (2,4) 6 (4,7) <0.001
T3 (24 h postoperatively) 3 (2,4.5) 5 (4,7) <0.001
T4 (48 h postoperatively) 3(2,5) 5 (4,6) <0.001
T5 (72 h postoperatively) 5 (3,6) 5 (3.5,6) 0.670

VAS, visual analogue scale; M, median value; IQR, interquartile range; PENG, pericapsular nerve group block; FICB, fascia iliac compartment block

The intraoperative remifentanil and cumulative postoperative fentanyl doses by PCIA within 24 h after surgery in PENG block group were significantly lower than those in FICB group (P < 0.001). However, no significant difference in the cumulative dose of postoperative fentanyl at 24–48 h was detected between groups (P = 0.396, Table 3). Compared with that of FICB group, postoperative analgesia satisfaction scores were significantly higher in PENG block group (P = 0.016, Table 3).

Table 3. Intraoperative and postoperative doses of opioid analgesics, and postoperative analgesia satisfaction scores.

Characteristics PENG Group (n = 25) FICB Group (n = 25) P
Intraoperative dose of remifentanil [μg, M (IQR)] 102 (95.5, 122.5) 186 (148, 215.5) <0.001
Cumulative dose of postoperative fentanyl [μg, M (IQR)]
 24 h postoperatively 0 (0, 20) 40 (20, 60) <0.001
 24–48 h postoperatively 40 (40, 60) 40 (20, 60) 0.396
Postoperative analgesia satisfaction scores [M (IQR)] 3 (3, 4) 3 (2, 3) 0.016

PENG, pericapsular nerve group block; FICB, fascia iliac compartment block; M, median value; IQR, interquartile range.

The incidence of quadriceps motor block was significantly higher in FICB group than that of PENG block group (48% vs. 0%, P < 0.001). Complications related to the nerve blocking such as local anesthetic poisoning, nerve injury, hematoma and hip infection were not reported in the two groups. We did not detect significant differences in the incidences of postoperative nausea, vomiting, dizziness, delirium, urinary retention and deep venous thrombosis of lower extremities between groups (all P > 0.05, Table 4).

Table 4. Incidences of quadriceps motor block and adverse events.

Characteristics [n (%)] PENG Group (n = 25) FICB Group (n = 25) P
Quadriceps motor block <0.001
 No block 25 (100) 13 (52)
 Paresis 0 (0) 8 (32)
 Paralysis 0 (0) 4 (16)
Nausea 1 (4) 4 (16) 0.349
Vomiting 0 (0) 0 (0) 1
Dizziness 1 (4) 2 (8) 1
Delirium 0 (0) 0 (0) 1
Urinary retention 0 (0) 0 (0) 1
Deep venous thrombosis of lower extremities 0 (0) 0 (0) 1

PENG, pericapsular nerve group block; FICB, fascia iliac compartment block.

Discussion

In our study, the primary analysis is analgesic effect of two different nerve block methods in elderly patients after PFNA. The secondary analysis is the effect of different nerve block methods on quadriceps femoris muscle strength. We also analyzed the safety of anesthesia related complications after nerve block surgery.

Compared to scoring before blocking, PENG block reduced exercising VAS pain scores by 7 points at 6 h after surgery (and 6 points 30 min after blocking), while FICB reduced exercising VAS pain scores by 2 and 3 points respectively at the same time points. The results suggested that patients who received PENG block had demonstrated significantly lower resting and exercising VAS scores and less opioid consumption during and after surgery than those who received FICB.

PENG block has been reported to provide adequate alagesia for fracture and dislocation of the hip joint, as well as total hip arthroplasty [911, 17]. On the other hand, FICB performed via anterior approach to the lumbar plexus, was reported to provide only moderate pain relief for hip surgery [18]. The reason for that lies in both magnetic resonance and autopsy studies confirming that FICB could not cover the obturator nerve [8, 19], while femoral obturator nerve block provides better analgesic effects than FICB for hip fracture [13]. In contrast, PENG targets obturator nerve and accessory obturator nerve specifically, as was demonstrated in previous cadaveric study [20]. In present study the majority of patients who received FICB suffered moderate to severe postoperative pain during exercising, indicating that FICB analgesia might be inadequate for IFF. These results are in line with the previous case reports suggesting that the inadequate analgesic effect of FICB is explained by the failure of obturator nerve block.

The preservation of quadriceps muscle strength is beneficial for early restoration of the daily function, as well as for minimizing the risk of fall during postoperative exercises [21]. As revealed in the previous study, PENG block did not weaken the quadriceps muscle strength, while FICB caused the decrease in 61% of patients [22]. While Aliste reported that the incidence of quadriceps movement block caused by PENG block 6h after surgery was 25%, while that of suprainguinal fascia iliaca compartment block (SFICB) was 85%. However, higher local anesthetic concentration was used in PENG block in this study than in this study [23]. Another study by Yu et al. [24] reported 2/100 cases of accidental quadriceps weakness following PENG block, which is caused by the spread of local anesthetic to the femoral nerve and iliac fascia space due to the medial and superficial position of the tip of puncture needle. As revealed in the present study, PENG block did not weaken the quadriceps muscle strength, while FICB caused the decrease in 48% of patients. It might be explained by the fact that PENG block targets the articular branch of femoral nerve, rather than the whole nerve, and as a result, the quadriceps muscle strength can be preserved.

This study has several limitations. Firstly, the sample size of this study was relatively small, and not powered to observe some rare complications. Secondly, adductor strength, hip joint functional recovery and length of hospital stay data were not collected. And finally the dose of fentanyl was controlled by patients, which may cause potential bias.

In conclusion, compared to FICB, ultrasound-guided PENG block provides better postoperative pain relief in patients with intertrochanteric femur fracture, with less pronounced quadriceps weakness. PENG block may be a good alternative analgesic method for hip fractures, and further large scale randomized clinical trials are needed.

Supporting information

S1 Checklist. CONSORT 2010 checklist of information to include when reporting a randomised trial*.

(DOC)

S1 Data

(XLSX)

Acknowledgments

We are very grateful to the Science & Technology Projects in Xuzhou for their funding and to all authors who have made contributions to the study work.

Declaration: All authors listed meet the authorship criteria according to the latest guidelines of the International Committee of Medical Journal Editors, and that all authors are in agreement with the manuscript.

Data Availability

The data that support the findings of this study are openly available in the following repositories: https://figshare.com/account/home#/data. The DOI is: https://10.6084/m9.figshare.21214463. The data are also in the Supporting information files.

Funding Statement

The author sreceived no specific funding for this work.

References

  • 1.Wu HF, Chang CH, Wang GJ, Lai KA, Chen CH. Biomechanical investigation of dynamic hip screw and wire fixation on an unstable intertrochanteric fracture. Biomed Eng Online 2019;18:49. doi: 10.1186/s12938-019-0663-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Foss NB, Kristensen BB, Bundgaard M, Bak M, Heiring C, Virkelyst C, et al. Fascia iliaca compartment blockade for acute pain control in hip fracture patients: a randomized, placebo-controlled trial. Anesthesiology 2007;106:773–8. doi: 10.1097/01.anes.0000264764.56544.d2 [DOI] [PubMed] [Google Scholar]
  • 3.Morrison SR, Magaziner J, McLaughlin MA, Orosz G, Silberzweig SB, Koval KJ, et al. The impact of post-operative pain on outcomes following hip fracture. Pain 2003;103:303–311. doi: 10.1016/S0304-3959(02)00458-X [DOI] [PubMed] [Google Scholar]
  • 4.Boddaert J, Raux M, Khiami F, Riou B. Perioperative management of elderly patients with hip fracture. Anesthesiology 2014;121:1336–41. doi: 10.1097/ALN.0000000000000478 [DOI] [PubMed] [Google Scholar]
  • 5.Stevens M, Harrison G, McGrail M. A modified fascia iliaca compartment block has significant morphine-sparing effect after total hip arthroplasty. Anaesth Intensive Care 2007;35:949–52. doi: 10.1177/0310057X0703500615 [DOI] [PubMed] [Google Scholar]
  • 6.Gao Y, Tan H, Sun R, Zhu J. Fascia iliaca compartment block reduces pain and opioid consumption after total hip arthroplasty: A systematic review and meta-analysis. Int J Surg 2019;65:70–79. doi: 10.1016/j.ijsu.2019.03.014 [DOI] [PubMed] [Google Scholar]
  • 7.Shariat AN, Hadzic A, Xu D, Shastri U, Kwofie K, Gandhi K, et al. Fascia lliaca block for analgesia after hip arthroplasty: a randomized double-blind, placebo-controlled trial. Reg Anesth Pain Med 2013;38:201–5. doi: 10.1097/AAP.0b013e31828a3c7c [DOI] [PubMed] [Google Scholar]
  • 8.Marhofer P, Nasel C, Sitzwohl C, Kapral S. Magnetic resonance imaging of the distribution of local anesthetic during the three-in-one block. Anesth Analg 2000;90:119–24. doi: 10.1097/00000539-200001000-00027 [DOI] [PubMed] [Google Scholar]
  • 9.Girón-Arango L, Peng PWH, Chin KJ, Brull R, Perlas A. Pericapsular Nerve Group (PENG) Block for Hip Fracture. Reg Anesth Pain Med 2018;43:859–863. doi: 10.1097/AAP.0000000000000847 [DOI] [PubMed] [Google Scholar]
  • 10.Sahoo RK, Jadon A, Sharma SK, Nair AS. Pericapsular nerve group (PENG) block for hip fractures: Another weapon in the armamentarium of anesthesiologists. J Anaesthesiol Clin Pharmacol. 2021. Apr-Jun;37(2):295–296. doi: 10.4103/joacp.JOACP_295_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wyatt K, Zidane M, Liu CJ. Utilization of a Continuous Pericapsular Nerve Group (PENG) Block with an Opioid-Sparing Repair of a Femoral Neck Fracture in a Pediatric Patient. Case Rep Orthop. 2020. Jul 14;2020:2516578. doi: 10.1155/2020/2516578 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Marsh JL, Slongo TF, Agel J, Broderick JS, Creevey W, DeCoster TA, et al. Fracture and dislocation classification compendium—2007: Orthopaedic Trauma Association classification, database and outcomes committee. J Orthop Trauma 2007;21:S1–133. doi: 10.1097/00005131-200711101-00001 [DOI] [PubMed] [Google Scholar]
  • 13.Zhou Y, Zhang W, Chong H, Xi Y,Wu X. A Prospective Study to Compare Analgesia from Femoral Obturator Nerve Block with Fascia Iliaca Compartment Block for Acute Preoperative Pain in Elderly Patients with Hip Fracture[J]. Medical science monitor: international medical journal of experimental and clinical research, 2019, 25:8562–8570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Dolan J, Williams A, Murney E, Smith M, Kenny GN. Ultrasound guided fascia iliaca block: a comparison with the loss of resistance technique. Reg Anesth Pain Med 2008;33:526–31. doi: 10.1016/j.rapm.2008.03.008 [DOI] [PubMed] [Google Scholar]
  • 15.Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011;63 Suppl 11:S240–52. [DOI] [PubMed] [Google Scholar]
  • 16.Bravo D, Layera S, Aliste J, Jara Á, Fernández D, Barrientos C, et al. Lumbar plexus block versus suprainguinal fascia iliaca block for total hip arthroplasty: A single-blinded, randomized trial. J Clin Anesth 2020;66:109907. doi: 10.1016/j.jclinane.2020.109907 [DOI] [PubMed] [Google Scholar]
  • 17.Anido Guzmán JA, Javier Robles Barragán F, Funcia de la Torre I, Alfonso Sanz F, Becerra Cayetano IA, de la Hoz Serrano C. Bilateral pericapsular nerves group (PENG) block for analgesia in pediatric hip surgery. Rev Esp Anestesiol Reanim (Engl Ed) 2021 [DOI] [PubMed] [Google Scholar]
  • 18.Swenson JD, Davis JJ, Stream JO, Crim JR, Burks RT, Greis PE. Local anesthetic injection deep to the fascia iliaca at the level of the inguinal ligament: the pattern of distribution and effects on the obturator nerve. J Clin Anesth 2015;27:652–7. doi: 10.1016/j.jclinane.2015.07.001 [DOI] [PubMed] [Google Scholar]
  • 19.Hebbard P, Ivanusic J, Sha S. Ultrasound-guided supra-inguinal fascia iliaca block: a cadaveric evaluation of a novel approach. Anaesthesia 2011;66:300–5. doi: 10.1111/j.1365-2044.2011.06628.x [DOI] [PubMed] [Google Scholar]
  • 20.Yamak Altinpulluk E, Galluccio F, Salazar C, Espinoza K, Olea MS, Hochberg U, et al. Peng block in prosthetic hip replacement: A cadaveric radiological evaluation. J Clin Anesth 2020;65:109888. doi: 10.1016/j.jclinane.2020.109888 [DOI] [PubMed] [Google Scholar]
  • 21.Ilfeld BM, Duke KB, Donohue MC. The association between lower extremity continuous peripheral nerve blocks and patient falls after knee and hip arthroplasty. Anesth Analg 2010;111:1552–4. doi: 10.1213/ANE.0b013e3181fb9507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yin H, Zhang W, Shan T, Tan Q, Bao H, Han L, et al. Comparison of efficacy of pericapsular nerve group block combined with lateral femoral cutaneous nerve block versus fascia iliaca compartment block in elderly patients undergoing total hip arthropl-asty under general anesthesia (China). Chin J Anesth 2021;41:567–570. [Google Scholar]
  • 23.Aliste J, Layera S, Bravo D, Jara Á, Muñoz G, Barrientos C, et al. Randomized comparison between pericapsular nerve group (PENG) block and suprainguinal fascia iliaca block for total hip arthroplasty. Reg Anesth Pain Med 2021;46:874–878. doi: 10.1136/rapm-2021-102997 [DOI] [PubMed] [Google Scholar]
  • 24.Yu HC, Moser JJ, Chu AY, Montgomery SH, Brown N, Endersby RVW. Inadvertent quadriceps weakness following the pericapsular nerve group (PENG) block. Reg Anesth Pain Med 2019;44:611–61 doi: 10.1136/rapm-2018-100354 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Ehab Farag

8 Jun 2022

PONE-D-22-10759The analgesic efficacy of pericapsular nerve group block in patients with intertrochanteric femur fracture: a randomized controlled trialPLOS ONE

Dear Dr. Mingjian Kong 

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================I would appreciate if you pay careful attention to the reviewers' comments in your response.==============================

Please submit your revised manuscript by Jul 23 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ehab Farag, MD FRCA FASA

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4 in your text; if accepted, production will need this reference to link the reader to the Table.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting study comparing Peripheral nerve blocks to Fascia iliaca compartment block. The manuscript to structured in a easy to read manner.

They a few comments worth addressing.

1. At the end of introduction, can the authors state the primary and secondary objectives.

2. Can the randomisation information include the allocation ratio.

3. Can the authors define their population of analysis for the primary analysis (e.g intent to treat), secondary and safety.

4. Table 1, as this this is an RCT, its recommended not to formally test baseline characteristics, any difference are simply due to chance and also do not serve a useful purpose so p-values should be omitted (see "Comparisons against baseline within randomised groups are often used and can be highly misleading by Bland JM, Altman 2011").

5. Any correction taken into account for multiple testing, i.e testing in each timepoint, increase you chance of finding a significant result?

6. Can the authors state whether a statistical analysis plan was signed off prior to unblinding?

7. Was there an oversight committee to monitor the safety of patients, its not mentioned in the manuscript?

Reviewer #2: Why do you think there was zero incidence of quadriceps motor weakness in the PENG block group compared to prior referenced studies that showed some degree of motor block, although still lower than fascia iliaca? You attributed it related to lower concentration or was the small sample size not adequately powered to detect secondary outcome measurements? Also would have been useful to measure quadriceps muscle strength at timepoints later than 6 hours

How was the method of passive exercise testing decided on? Is there a basis for using a 15 degree passive hip elevation?

How long after block performance were patients induced and surgery started? As t1 is 30 min post block time, does an increased length of time between block performance and starting the timer at the conclusion of surgery influence block duration when measured postop? The length of surgical time is shown but not the length of time between T1 and T2.

Source 13 does not refer to anything relevant to this study - need to edit this

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Oct 13;17(10):e0275793. doi: 10.1371/journal.pone.0275793.r002

Author response to Decision Letter 0


1 Aug 2022

Editor

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

Respected Editors:thanks for your review , modifications have been made in the manuscript as requested.

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Respected Editors:we have uploaded a separate minimal data.

3. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4 in your text; if accepted, production will need this reference to link the reader to the Table.

Respected Editors:we have modified this and marked it in the manuscript.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Respected Editors:We have added the title of the supporting information file to the end of the manuscript.

5.Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Respected Editors:We have checked the reference list and made corrections to ensure it is complete and correct.(all revisions have been marked in the manuscript)

Reviewer 1

1.At the end of introduction, can the authors state the primary and secondary objectives.

It has been supplemented in the introduction section of the manuscript.We will be happy to edit the text further, based on helpful comments from the reviewers.

2.Can the randomisation information include the allocation ratio.

It has been supplemented in the Randomization and Blinding section of the manuscript.We will be happy to edit the text further, based on helpful comments from the reviewers.

3.Can the authors define their population of analysis for the primary analysis (e.g intent to treat), secondary and safety.

It has been supplemented in the discussion section of the manuscript.We will be happy to edit the text further, based on helpful comments from the reviewers.

4.Table 1, as this this is an RCT, its recommended not to formally test baseline characteristics, any difference are simply due to chance and also do not serve a useful purpose so p-values should be omitted (see "Comparisons against baseline within randomised groups are often used and can be highly misleading by Bland JM, Altman 2011").

We thank the reviewer for pointing out thi issue.We studied the document you provided and found that there was a misunderstanding. The baseline written on the form was a clerical error and has been deleted in the text. In our research groups were be compared directly by two-sample methods.

5.Any correction taken into account for multiple testing, i.e testing in each timepoint, increase you chance of finding a significant result?

We thank the reviewer for pointing out thi issue. We have taken this situation into consideration,VAS score belongs to grade data and does not conform to the normal distribution, so we use the median (interquartile spacing) for statistical description, and use Kruskal Wallis H test to get the result P < 0.05. It can be considered that the distribution of scores in each group is not the same, and the difference is statistically significant, and then compare them at different time points to find out the positive results.

6.Can the authors state whether a statistical analysis plan was signed off prior to unblinding?

This study developed a statistical analysis plan before Unblinding. The staff who conducted the data analysis did not understand the processing methods of each group. They only selected the corresponding statistical analysis method according to the type of data collected, and then unblinded after completing the statistical analysis of each group of data.

7. Was there an oversight committee to monitor the safety of patients, its not mentioned in the manuscript?

The Ethics Committee supervised the implementation of this study and protected the rights and interests of patients. Relevant contents have been supplemented in the study design and subjects section of the manuscript.

Reviewer 2

Why do you think there was zero incidence of quadriceps motor weakness in the PENG block group compared to prior referenced studies that showed some degree of motor block, although still lower than fascia iliaca? You attributed it related to lower concentration or was the small sample size not adequately powered to detect secondary outcome measurements? Also would have been useful to measure quadriceps muscle strength at timepoints later than 6 hours.

We thank the reviewer for pointing out thi issue.We consider that this situation may be the reason for the concentration. The reference study nerve block used 0.5% ropivacaine, and this study used 0.375% ropivacaine.

In addition to the time point of 6 hours after operation, we also measured the quadriceps femoris muscle strength at 12 hours and 24 hours after operation, but there was no positive result, so it was not included in the result.

How was the method of passive exercise testing decided on? Is there a basis for using a 15 degree passive hip elevation?

We refer to reference 15 for the specific methods of passive motion testing.We will be happy to edit the text further, based on helpful comments from the reviewers.

How long after block performance were patients induced and surgery started? As t1 is 30 min post block time, does an increased length of time between block performance and starting the timer at the conclusion of surgery influence block duration when measured postop? The length of surgical time is shown but not the length of time between T1 and T2.

We thank the reviewer for pointing out thi issue.We made statistics on T1-T2 of patients in each group, and the results were not statistically significant. Table1 has been supplemented with relevant data.

Attachment

Submitted filename: Response to Reviewers.doc

Decision Letter 1

Rizaldy Taslim Pinzon

26 Sep 2022

The analgesic efficacy of pericapsular nerve group block in patients with intertrochanteric femur fracture: a randomized controlled trial

PONE-D-22-10759R1

Dear Dr. Kong

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Rizaldy Taslim Pinzon

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for addressing comments from the previous submission. The included tables and figures bring added clarity to the data and results.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Thank you for addressing comments from the previous submission. The included tables and figures bring added clarity to the data and results.

One comment would be for the addition to the beginning of the discussion section: "We also

analyzed the safety of anesthesia related complications after nerve block surgery" - this sentence is unclear, the word surgery probably should not be included after nerve block.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Acceptance letter

Rizaldy Taslim Pinzon

2 Oct 2022

PONE-D-22-10759R1

The analgesic efficacy of pericapsular nerve group block in patients with intertrochanteric femur fracture: a randomized controlled trial

Dear Dr. Kong:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Rizaldy Taslim Pinzon

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. CONSORT 2010 checklist of information to include when reporting a randomised trial*.

    (DOC)

    S1 Data

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.doc

    Data Availability Statement

    The data that support the findings of this study are openly available in the following repositories: https://figshare.com/account/home#/data. The DOI is: https://10.6084/m9.figshare.21214463. The data are also in the Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES